Shilpa Medicare Limited

| Updated on January 15, 2018 Published on April 12, 2017

Shilpa Medicare said on Wednesday that the US health regulator has issued an Establishment Inspection Report (EIR) for its manufacturing facilities at Raichur in Karnataka. The USFDA has issued the EIR for the company’s Active Pharmaceutical Ingredient manufacturing facilities, which were inspected between December 12 and 16, 2016. The inspection has now been closed by the USFDA, Shilpa Medicare said in a BSE filing. The company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the Form 483 issued at the end of the inspection. The USFDA has reviewed the CAPA and has found it acceptable. Shares of Shilpa Medicare surged 5.3 per cent at ₹718.65 on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on April 12, 2017
This article is closed for comments.
Please Email the Editor